Nodular lymphocyte-predominant Hodgkin lymphoma

被引：3

作者：

Fuchs M. ^{[1
]}

Eichenauer D.A. ^{[1
]}

Nogová L. ^{[1
]}

Diehl V. ^{[1
]}

Engert A. ^{[1
]}

机构：

[1] First Department of Internal Medicine, University Hospital of Cologne, 50924 Cologne

来源：

Current Hematologic Malignancy Reports | 2008年 / 3卷 / 3期

关键词：

Hodgkin Lymphoma; Nodular Lymphocyte Predominant Hodgkin Lymphoma; Mediastinal Involvement; German Hodgkin Study Group; British National Lymphoma Investigation;

D O I：

10.1007/s11899-008-0019-5

中图分类号：

学科分类号：

摘要：

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare subtype of Hodgkin lymphoma that differs from classic Hodgkin lymphoma (cHL) with respect to histologic and clinical presentation. Because the prognosis of NLPHL in early unfavorable and advanced stages is similar to that of cHL, treatment is similar. In contrast, early favorable-stage NLPHL has a better prognosis than cHL. Thus, NLPHL in early favorable stages might be treated with reduced-intensity programs without compromising cure rates. Because involved-field radiotherapy alone seems to be as effective as extended-field radiotherapy or combined modalities, it has been adopted by the German Hodgkin Study Group and the European Organisation for Research and Treatment of Cancer as the treatment of choice for stage IA NLPHL. Now that efficacy of the monoclonal antibody rituximab has been shown in relapsed NLPHL, its use in the first-line treatment of NLPHL is under investigation. Copyright © 2008 by Current Medicine Group LLC.

引用

页码：126 / 131

页数：5

共 30 条

[1]

Jost L.M., Stahel R.A., ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of Hodgkin's disease, Ann Oncol, 16, SUPPL. 1, (2005)

[2]

Ries L.A., Kosary C.L., Hankey B.F., Et al., SEER Cancer Statistics Review: 1973-1994, (1997)

[3]

Diehl V., Sextro M., Franklin J., Et al., Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: Report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease, J Clin Oncol, 17, pp. 776-783, (1999)

[4]

Anagnostopoulos I., Hansmann M.L., Franssila K., Et al., European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: Histologic and immuno-histologic analysts of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes, Blood, 96, pp. 1889-1899, (2000)

[5]

Trudel M.A., Krikorian J.G., Neiman R.S., Lymphocyte predominance Hodgkin's disease. A clinicopathologic reassessment, Cancer, 59, pp. 99-106, (1987)

[6]

Pappa V.I., Norton A.J., Gupta R.K., Et al., Nodular type of lymphocyte predominant Hodgkin's disease. A clinical study of 50 cases, Ann Oncol, 6, pp. 559-565, (1995)

[7]

Nogova L., Reineke T., Eich H.T., Et al., Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: A retrospective analysis from the German Hodgkin Study Group (GHSG), Ann Oncol, 16, pp. 1683-1687, (2005)

[8]

Ekstrand B.C., Lucas J.B., Horwitz S.M., Et al., Rituximab in lymphocyte-predominant Hodgkin disease: Results of a phase 2 trial, Blood, 101, pp. 4285-4289, (2003)

[9]

Pellegrino B., Terrier-Lacombe M.J., Oberlin O., Et al., Lymphocyte- predominant Hodgkin's lymphoma in children: Therapeutic abstention after initial lymph node resection-a Study of the French Society of Pediatric Oncology, J Clin Oncol, 21, pp. 2948-2952, (2003)

[10]

Mauz-Korholz C., Gorde-Grosjean S., Hasenclever D., Et al., Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma, Cancer, 110, pp. 179-185, (2007)

← 1 2 3 →